{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"6","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Measured from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR.","id":"OG000","title":"Gemcitabine and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"All eligible patients who started treatment were included in this measure.","reportingStatus":"POSTED","timeFrame":"0 - 3 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}